Oncolytics Biotech Inc. (ONCY) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

Oncolytics Biotech Inc.

NASDAQ: ONCY · Real-Time Price · USD
1.06
-0.02 (-1.85%)
At close: Sep 05, 2025, 3:59 PM
1.06
0.00%
After-hours: Sep 05, 2025, 07:29 PM EDT

Company Description

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.

Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.

Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC.

The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc.
Oncolytics Biotech Inc. logo
Country CA
IPO Date Oct 5, 2001
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Wayne F. Pisano

Contact Details

Address:
322 11th Avenue SW
Calgary, AB
CA
Website https://www.oncolyticsbiotech.com

Stock Details

Ticker Symbol ONCY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001129928
CUSIP Number 682310875
ISIN Number CA6823108759
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Wayne F. Pisano M.B.A. Interim Chief Executive Officer & Chairman of the Board
Kirk J. Look C.A., CPA Chief Financial Officer
Allison Hagerman P.Eng., P.M.P. Vice President of Product Development
Amy Goodowitz Levin B.S.N., R.N. Vice President of Clinical Operations
Christophe Degois Vice President of Business Development
Dr. Thomas C. Heineman M.D., Ph.D. Chief Medical Officer
John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. Consultant
Jon Patton Director of Investor Relations & Communication

Latest SEC Filings

Date Type Title
Sep 02, 2025 6-K Filing
Aug 28, 2025 6-K Filing
Aug 22, 2025 F-3 Filing
Aug 11, 2025 6-K Filing
Aug 08, 2025 6-K Filing
Aug 08, 2025 6-K Filing
Aug 08, 2025 6-K Filing
Aug 08, 2025 6-K Filing
Aug 05, 2025 6-K Filing
Jul 29, 2025 6-K Filing